Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stoke Therapeutics, Inc. (Nasdaq: STOK) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures. As a Nasdaq Global Select Market issuer, Stoke files current reports, annual reports, and other documents that describe its financial condition, governance, and progress in developing RNA-based medicines such as zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Current reports on Form 8-K document material events, including quarterly financial results, clinical and collaboration milestones, and changes in executive leadership. For example, Stoke has used Form 8-K to announce results of operations, disclose the appointment of its Chief Executive Officer and related employment and severance agreements, and furnish press releases about the initiation and progress of the global Phase 3 EMPEROR study of zorevunersen and the Phase 1 OSPREY study of STK-002.
Amended current reports on Form 8-K/A provide additional detail or updates on previously reported items, such as the company’s decisions regarding the frequency of advisory shareholder votes on executive compensation. These filings offer insight into Stoke’s corporate governance practices and board decisions.
Through Stock Titan, investors can also track periodic filings such as Forms 10-K and 10-Q when available, which typically include detailed discussions of Stoke’s TANGO antisense platform, its rare disease pipeline, collaboration agreements, and risk factors. Form 4 and related insider transaction filings, when present, can help users monitor equity awards and share transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand the significance of items such as clinical trial disclosures, collaboration terms, compensation arrangements, and shareholder voting outcomes. Real-time updates from the SEC’s EDGAR system ensure that new STOK filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are surfaced promptly for further review and analysis.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, executed an open-market sale of 1,838 shares of Common Stock. The shares were sold at an average price of $32.66 per share. After this transaction, he continues to hold 38,864 shares directly.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, indicating the transaction was scheduled in advance rather than timed discretionarily.
Insider proposed sales under Rule 144. The excerpt lists 10b5-1 sales by Baruch S. Ticho of Common stock for 1,461 shares on 03/19/2026 ($43,815.39), 6,686 shares on 03/18/2026 ($209,568.72), and 6,164 shares on 03/17/2026 ($203,450.99). It also shows 1838 Restricted Stock Units dated 12/01/2025.
Stoke Therapeutics changed its independent auditor, dismissing KPMG LLP and appointing Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
The company states that KPMG’s audit reports for 2024 and 2025 contained no adverse or qualified opinions, and there were no disagreements or reportable events under SEC rules through March 23, 2026. KPMG provided a letter to the SEC agreeing with these disclosures, which is included as an exhibit.
The Vanguard Group filed an amendment to its Schedule 13G on behalf of its reporting entity to state it holds 0 shares of Stoke Therapeutics Inc. common stock following an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries' holdings under SEC Release No. 34-39538. The amendment is signed by a Vanguard officer on March 27, 2026.
Stoke Therapeutics general counsel Jonathan Allan sold 9,293 shares of common stock in open-market transactions. The sales occurred on March 20, 2026 at weighted average prices of $33.64 and $34.41 per share under a pre-arranged Rule 10b5-1 trading plan. He continues to hold 19,543 shares directly after these trades.
STOK filed a Form 144 notice reporting an affiliate sale plan. The filing lists 9,293 restricted stock units to be sold and shows two reported sales by Jonathan Allan on 03/17/2026 (4,267 shares) and 03/18/2026 (4,628 shares) with cash amounts shown.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, reported an option exercise and related share sales. He exercised a stock option for 1,365 shares of common stock at $2.19 per share and then sold a total of 14,311 shares in open-market transactions at prices between $29.99 and $33.855 per share.
The filing notes that part of the activity was an issuer-mandated sale to cover tax withholding tied to restricted stock unit vesting, and that transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025. Following these transactions, Ticho directly holds 40,702 shares of Stoke Therapeutics common stock, with the reported option now fully vested and exercisable.
Stoke Therapeutics, Inc. Chief Financial Officer Thomas Leggett reported issuer-mandated sales of 4,578 shares of common stock on March 17–18, 2026 to satisfy tax withholding obligations tied to vesting of restricted stock units. The shares were sold in multiple open-market transactions at weighted-average prices generally in the low‑$30s, with individual trades ranging from $30.59 to $33.855 per share. Following these transactions, he directly holds 10,172 shares of Stoke Therapeutics common stock, indicating the activity was a tax-related disposition rather than a complete exit from his equity position.
Stoke Therapeutics Chief Patient Officer Jason Hoitt reported mandated share sales to cover taxes on vested stock units. On March 17–18, 2026, he sold a total of 3,712 shares of common stock in open-market transactions required to satisfy tax withholding obligations. Sale prices were based on weighted averages, with individual trades occurring in ranges between $30.59 and $33.855 per share. After these transactions, he directly holds 10,276 shares, and no remaining stock options or other derivatives are reported.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported open‑market sales of 8,895 shares of common stock in multiple transactions on March 17–18. A footnote states these sales were issuer‑mandated to satisfy tax withholding liabilities from vesting restricted stock units. After the transactions, he holds 28,836 shares of common stock directly.